ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

trifarotene

Also written as “Trifarotene”, “Trifarotene Cream 0.005%” and “Trifarotene Cream”.

Its studies are mostly in Acne Vulgaris · Ichthyosis, Lamellar, led by 4 companies.

Drug pageTrifarotene: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 25, 202013 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Galderma Groupits history only91 open or runningphase 4since Jun 25, 2020Jun 8, 2012Dec 31, 2026phase 3 · NCT07186413
Sun Pharmaceutical Industriesits history only20 open or runningphase 1since Sep 20, 2023Sep 20, 2023none ahead
Mayne Pharma International Pty10 open or runningphase 2since Oct 24, 2018Oct 24, 2018none ahead
Teva Pharmaceutical Industriesits history only10 open or runningphase 3since Sep 19, 2022Sep 19, 2022none ahead

Also a collaborator on its studies: Teva Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Mayne Pharma International Pty only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 24, 2018First study: phase 2 study in Ichthyosis, LamellarFirst studyNCT03738800 · 65 enrolled · United States, Australia, Canada and more

TargetBeta

RARG →read by rule
“Retinoic acid receptor gamma agonist”ChEMBL 37, by rule

Other programs on RARG

ProgramCompanyFurthest phaseStudies
PalovaroteneruleIpsenphase 310

Studies

The one study Mayne Pharma International Pty leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03738800Ichthyosis, Lamellar · United States, Australia, Canada and more2TerminatedSep 3, 202165

How it is read

Names in the registry

  • “Trifarotene”, 2 entries
  • “Trifarotene Cream 0.005%”, 2 entries
  • “Trifarotene Cream”, 2 entries
  • “Trifarotene 0.005 % Topical Cream”, 1 entry
  • “CD5789 Cream 200 µg/g”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.